After signing up, you'll start to receive regular news updates from us.
QIAGEN Enhances its Range of High-Throughput RNAi Solutions
Complete the form below to unlock access to ALL audio articles.
QIAGEN has enhanced its range of high-throughput RNAi solutions with the launch of the Human Whole Genome siRNA Set V4.0, the Human Druggable Genome siRNA Set V4.0, and subsets for GPCRs, phosphatases, and kinases.
siRNAs are designed using QIAGEN’s HP OnGuard siRNA Design which incorporates many features and delivers potent and specific siRNA.
HP OnGuard siRNA Design integrates neural network technology, proprietary homology analysis, and asymmetry analysis. The latest knowledge on the mechanism of miRNA-related off-target effects is used in the design of multi-parameter, seed-region searches.
siRNA design also takes advantage of the results of large-scale, wet-lab siRNA validation studies and genomewide analysis using Affymetrix® GeneChip® arrays. Up-to-date sequence information is used for SNP and interferon motif avoidance.
siRNA Sets are provided in flexible scales and formats, including individual siRNAs or pools, to suit specific screening requirements. The Human Whole Genome siRNA Set V4.0 targets 19,121 human genes (NM genes) and a supplemental set targeting 5318 predicted (XM) genes is also available.
The Human Druggable Genome siRNA Set V4.0 targets 6961 genes of potential therapeutic value. Subsets target 490 GPCR genes, 696 kinase genes, or 205 phosphatase genes.
siRNA Sets are provided with complete siRNA sequence disclosure at no extra cost. All rights to any invention or discovery developed by researchers using these sequences belong to the researcher, allowing complete freedom for discovery.
